Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 ( Rexaceract) in People with Parkinson’s Disease Location : Hall D, 3 rd Floor, E-Poster Station 12 The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field's clinicians,

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease,

Forbes contributors publish independent expert analyses and insights. Daryl Austin is a Utah-based reporter who covers health and wellness. April is Parkinson’s Awareness Month, and even though we know more about the disease than ever before, about ...

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

AbbVie’s JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

New information is emerging about Dennis Haskins‘ health following his death at 75. Kimberly Snow, a friend and caretaker of the Saved by the Bell alum, told The New York Times following news of his death on Sunday,